VistaGen Therapeutics, Inc.

Our CEO, Shawn Singh, discussed VistaGen, our PALISADE-1 Phase 3 trial for the development of PH94B for the acute treatment of anxiety in adults with social anxiety disorder, and the importance of mental health at the William Blair 41st Annual Growth Stock Conference.

PH94B has the potential to provide adults suffering from social anxiety disorder with an acute, as-needed treatment of anxiety, similar to how a rescue inhaler is used to prevent an asthma attack. Learn more about PH94B and our recently initiated PALISADE-1 Phase 3 trial here:

VistaGen will be added to the Russell 2000 Index at the conclusion of the 2021 Russell Indexes annual reconstitution, effective after the U.S. market opens on Monday, June 28, according to a preliminary list of additions posted on June 4. Learn more:

In the aftermath of Naomi Osaka's open discussion about her mental health struggles and withdrawal from the 2021 French Open, USA Today highlights how celebrities are helping to bring mental health conversations to the spotlight:

Shawn Singh provided a corporate overview at last week's Jefferies Virtual Healthcare Conference, highlighting the Company's pipeline of new generation CNS drug candidates, including PH94B which recently initiated its Phase 3 trial for the treatment of SAD.

Shawn Singh discusses the ongoing mental health pandemic and benzodiazepine crisis, and highlights VistaGen's work to go beyond the current standard for care for anxiety, depression and other CNS disorders. Listen via the Stock2Me podcast:

Giselle Appel highlights the FDA's recent Boxed Warning changes for benzodiazepines and addresses the dangers of benzo use within the geriatric population.

A new poll from the American Psychiatric Association (APA) showed 62% of Americans feel more anxious than they did at this time last year. This data further demonstrates the need to make mental health issues a priority in the US.

In a mental health crisis, seconds matter. Shawn Singh praises the new 3-digit suicide hotline, and discusses the importance of destigmatizing mental illness:

STAT reports on the recently announced EverInsight and AffaMed merger including the combined company's portfolio of therapies for neurological and psychiatric disorders including PH94B:

Shawn Singh joins Psychiatric Times to highlight the growing mental health pandemic in the wake of COVID-19 and how the current standard of care for anxiety and depression disorders falls short of patient needs. Learn more about our mission to develop rapid-acting and safe anxiety and depression treatments that are fundamentally different from current treatments:

Psychiatric Times highlights our development of PH94B for social anxiety disorder following the FDA's announcement of new Boxed Warning for risks associated with benzodiazepines.

For people with social anxiety disorder, virtual communication can be just as stressful and anxiety-inducing as conversing in-person. Metro reports:

EverInsight’s merger with AffaMed will add PH94B to AffaMed’s pipeline of innovative CNS candidates. AffaMed will develop & commercialize PH94B for anxiety disorders in key Asian Markets as part of the strategic collaboration with VistaGen announced in June 2020

The FDA's recently announced benzodiazepine Box Warning changes emphasize the potentially harmful side effects and dangers associated with long-term benzodiazepine use. VistaGen's PH94B’s has the potential to treat multiple anxiety disorders without the side effects and safety concerns associated with benzodiazepines. Learn more:

VistaGen's PH94B has the potential to provide rapid, on-demand anxiety relief for the millions of people who suffer from social anxiety disorder. Dr. Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board member and principal investigator of the Company’s planned Ph. 3 study shares his optimism for the future of anxiety treatments including the development of new rapid onset treatments like VistaGen's PH94B.

The BIO Investor Forum Digital is going on now! Register to watch VistaGen's on-demand presentation highlighting the differentiated mechanisms of action of PH94B, PH10 and AV-101 with therapeutic potential in multiple global CNS markets:

Nasdaq Grants VistaGen 180-Day Extension to Meet Minimum Bid Price Requirement: